

16 July, 2010  
MEDRx Co Ltd.

## **Start of Phase III Clinical Trial for MRX-7EAT in Patients with Acute Pain**

MEDRx Co. Ltd. (a Japanese pharmaceuticals company located in Kagawa, Japan: hereinafter called MEDRx) announces MEDRx and IL Pharma Inc. (a subsidiary of MEDRx Co., Ltd.: hereinafter called ILP) has been just starting a randomized, multi-center, double-blind, placebo-controlled Phase III clinical trials for MRX-7EAT (Etodolac-Lidocaine Topical Patch) in the treatment of acute pain.

MRX-7EAT is a pharmaceutical topical patch containing etodolac, one of non-steroidal anti-inflammation drugs. The oral etodolac products have been widely known and used to relieve pain and inflammation. However, MRX-7EAT will be the first topical etodolac patch in the world. The results of non-clinical studies in some animals have shown the safety and efficacy of MRX-7EAT. And the results of Phase I clinical trials in human have also shown the safety and tolerability.

MEDRx/ILP evaluate the efficacy, tolerability and safety of MRX-7EAT on Phase III clinical trials in patients with acute pain.

[FOR DETAILS, SEND E-mail at info@medrx.co.jp](mailto:info@medrx.co.jp)